Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Veracyte, Inc.

< Previous 1 2 3 4 5 Next >
Veracyte to Participate in the Stephens Annual Investment Conference
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Second Quarter 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces First Quarter 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Release of Inaugural ESG Report
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.